Zacks Small Cap Weighs in on ABVC BioPharma, Inc.'s Q1 2023 Earnings (OTCMKTS:ABVC)
Zacks Small Cap Weighs in on ABVC BioPharma, Inc.'s Q1 2023 Earnings (OTCMKTS:ABVC)
ABVC BioPharma, Inc. (OTCMKTS:ABVC – Get Rating) – Zacks Small Cap issued their Q1 2023 EPS estimates for ABVC BioPharma in a report issued on Wednesday, January 18th. Zacks Small Cap analyst M. Marin anticipates that the company will post earnings per share of ($0.05) for the quarter. The consensus estimate for ABVC BioPharma's current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for ABVC BioPharma's Q2 2023 earnings at ($0.06) EPS, Q3 2023 earnings at ($0.05) EPS and Q4 2023 earnings at ($0.04) EPS.
ABVC 生物製藥公司(OTCMKTS:ABVC-獲得評級)-扎克斯小型股在 1 月 18 日星期三發布的一份報告中發布了其 2023 年第一季度 ABVC 生物製藥的估計。扎克斯小型股分析師馬林預計,該公司將在本季度發布每股收益(0.05 美元)。ABVC 生物製藥目前全年盈利的共識估計為每股 0.56 美元。扎克斯小型股還發布了 ABVC 生物製藥 2023 年第二季度盈利(0.06 美元),2023 年第三季盈利為每股盈利(0.05 美元)和 2023 年第四季盈利(0.04 美元)的估計值。
Separately, Maxim Group downgraded shares of ABVC BioPharma from a "buy" rating to a "hold" rating in a research note on Wednesday, November 16th.
另外,美心集團於 11 月 16 日(星期三)的研究報告中,將 ABVC 生物製藥的股份從「買入」評級下調至「持有」評級。
ABVC BioPharma Stock Performance
ABVC 生物製藥股票表現
ABVC BioPharma (OTCMKTS:ABVC – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.03 million.
ABVC 生物製藥(OTCMKTS:ABVC-獲取評級)上次公佈其季度業績於 11 月 14 日(星期一)。該公司報告了本季度每股盈利(0.11 美元),頂部分析師的共識估計(0.20 美元)為 0.09 美元。該公司本季的營收為 0.04 萬美元,而分析師的預期為 0.3 萬美元。
About ABVC BioPharma
關於 ABVC 生物製藥
(Get Rating)
(取得評分)
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
ABVC BioHharma, Inc. 是一家臨床階段生物製藥公司,致力於開發藥物和醫療設備,以滿足美國未滿足的醫療需求。公司正在開發 ABV-1501,目前正在進行 I/II 期臨床試驗,一種三陰性乳腺癌的聯合療法;ABV-1504 已完成重大抑鬱症的 II 期臨床試驗;ABV-1505 已完成治療胰腺癌的 I 期臨床試驗;已完成治療骨髓增生障礙的 I 期臨床試驗;ABV-1703 已完成治療胰腺癌的 I 期臨床試驗;治療癌症患者抑鬱症的臨床試驗;及 ABV-1702 ABV-1601ABV-1701 用於治療視網膜脫落或玻璃體出血的治療。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on ABVC BioPharma (ABVC)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 獲取有關 ABVC 生物製藥研究報告的免費副本
- 市場節拍週的回顧 — 1/16 — 1/20
- 老自治領是否顯示卡車正在擊中剎車?
- 諾德斯特龍將對減價的恐懼放入零售業
- 埃克森美孚股票:在買入點的醒目距離內
- 高股息收益的必和必拓認為中國推動 23 年增長
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 ABVC 生物製藥的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 ABVC 生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。